Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085958 | 0.90 | HSD17B10 (0.43) | TACR2TACR1SSTR5PKMLMNA | |
| SCHEMBL4502178 | 0.84 | MMP2 (0.40) | TACR2TACR1SSTR5ALDH1A1SMN1; SMN2 | |
| SCHEMBL1086737 | 0.82 | TACR2 (0.51) | TACR2TACR1 | |
| SCHEMBL4498285 | 0.82 | PKM (0.43) | SSTR5PKMALDH1A1LMNAGAA | |
| SCHEMBL1086606 | 0.80 | ALDH1A1 (0.48) | PKMALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL18445998 | 0.79 | TACR2 (0.48) | TACR2TACR1ALDH1A1HTT | |
| SCHEMBL1086684 | 0.75 | PKM (0.43) | PKMALDH1A1LMNAGAAHTT | |
| SCHEMBL1086446 | 0.75 | HSD17B10 (0.42) | ALDH1A1LMNAHTT | |
| SCHEMBL1086523 | 0.74 | TP53 (0.44) | TACR2TACR1ALDH1A1GAA | |
| SCHEMBL1086574 | 0.74 | KDM4E (0.45) | TACR2TACR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | TACR2 1923/4885TACR1 1796/4885SSTR5 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.